tirzepatide approval in canada FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes Variety Pack The State of Peptides Dosis:30 mg

tirzepatide approval in canada FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes Variety Pack The State of Peptides Dosis:30 mg

The State of Peptides 2026 — Chapter 3: The Pipeline. The next drugs — led by retatrutide, the most consequential molecule since semaglutide. Read the full report (free) → link in bio #peptides #stateofpeptides #glp1

For instance, in January 2025, the U.S

Variety Pack

Dosis:30 mg

GLP-1 agonist medications include: Wegovy®* and Ozempic®* (Semaglutide) Zepbound®* and Mounjaro®* (Tirzepatide) Saxenda®* and Victoza®* (Liraglutide) As agonist medications, these medications mimic the GLP-1 hormone and increase its effect around the clock